The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention

N Engl J Med. 2011 Jul 14;365(2):97-9. doi: 10.1056/NEJMp1106783. Epub 2011 Jun 15.

Authors

Marc R Theoret¹, Yang-Min Ning, Jenny J Zhang, Robert Justice, Patricia Keegan, Richard Pazdur

Affiliation

¹ Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.

PMID: 21675880
DOI: 10.1056/NEJMp1106783

No abstract available

MeSH terms

5-alpha Reductase Inhibitors / adverse effects
5-alpha Reductase Inhibitors / therapeutic use*
Azasteroids / adverse effects
Azasteroids / therapeutic use
Drug Approval*
Dutasteride
Finasteride / adverse effects
Finasteride / therapeutic use
Humans
Incidence
Male
Prostatic Neoplasms / epidemiology
Prostatic Neoplasms / pathology
Prostatic Neoplasms / prevention & control*
United States
United States Food and Drug Administration

Substances

5-alpha Reductase Inhibitors
Azasteroids
Finasteride
Dutasteride